摘要
重组人LFA-3/IgG1融合蛋白Alefacept通过特异性地阻断APC-T细胞与LFA-3/CD2的结合而抑制T细胞的活性,引起CD4+、CD8+记忆T细胞凋亡,从而达到治疗银屑病的目的。它比其他治疗银屑病的方法更有效、更安全,成为当今免疫学研究的重点方向之一。本文介绍了Alefacept治疗银屑病的作用机理、临床应用、毒性反应,及药代动力学研究进展。
Alefacept inhibit the activity of T ceils through obstructing the bind of APC-T dells and LFA-3/CD2 specifically, which cause the apoptosis of CD4^+, CD8^+ remembrance T cells and touch the aim of treating psoriasis. It's a method more effect and safer than others and becomes one of study emphasis. This paper introduced the mechanism of action, clinical application, noxious reaction, the progression dynamics of drug metabolism about alefacept curing psoriasis.
出处
《生物技术通讯》
CAS
2006年第2期262-264,共3页
Letters in Biotechnology